The key facts

  • 40 INNs of drugs from the VED list have been registered that had not previously been produced in Russia, 15 of them in 2026
  • The goal is to reduce dependence on foreign supplies and ensure lower prices
  • The Russian drug 'Angipur' for use in myocardial infarction may reach the market within the next two years

Registration of drugs from the list of vital and essential medicines

Russian pharmaceutical companies have registered 40 international nonproprietary names (INNs) of medicines from the list of vital and essential drugs (VED) that had not previously been produced in Russia. This was announced by the press service of the office of Deputy Prime Minister Tatyana Golikova, reports Gazeta.Ru citing TASS. Of this number, 15 names were registered in 2026 under the federal project 'Development of the Production of the Most In-Demand Medicines and Medical Devices'.

Stated goals and upcoming new products

The Deputy Prime Minister's office clarified that domestic production of these drugs should reduce dependence on foreign supplies and provide the national healthcare system with vital medicines at a lower price.

'Angipur': full localization of production

Dean of the Faculty of Pharmacy at Volgograd State Medical University, Doctor of Pharmaceutical Sciences Viktor Sirotenko said, that the Russian drug 'Angipur', intended for use in myocardial infarction, may appear on the market within the next two years. According to him, the drug is meant to replace imported analogues whose supply is problematic, and the entire cycle — from synthesis of the active substance to production of the finished drug — is carried out in Russia, so production does not depend on foreign substances, equipment or consumables.

Context

It was previously reported that in Russia, a unique drug for liver cancer was successfully tested.